Inventiva Pharma - IVA Net earnings per one share for the last twelve months

Inventiva Corp (IVA) - corporate logo

The development of innovative liver fibrosis therapies is driving a positive trend, and GURU.Markets provides this annual EPS (TTM) growth chart, where 66.50 reflects the current value of the metric for Inventiva S.A. (IVA). The business model relies on outsourced production via CMO partners, while the stability of international clinical trials is supported by minimal geopolitical pressure on the pharmaceutical sector.

Inventiva - IVA Net earnings per share (EPS TTM) (period 02/11/2024 - 11/15/2026)

Financial and market metric breakdowns for Inventiva S.A. (IVA)

- share price and expert price forecast:
Price Chart Inventiva|IVA - Analyst Consensus Forecast
- issuer market value details:
Market Value Inventiva Corp|IVA - Total Company Value
- company book value details:
Accounting Value of a Share Inventiva|IVA - Book Capitalization|Market Capitalization to Book Value inventivapharma.com|IVA - Aggregate Company Assets
- debt and liquidity data:
Debt to Equity Ratio Inventiva S.A.|IVA - Long-Term Debt to Equity Ratio|Short-Term Debt to Equity Inventiva S.A.|IVA - Company Aggregate Debts|Debts to Book Value Inventiva Corp|IVA - Company Long-Term Debt|Company Short-Term Indebtedness Inventiva|Intermediate Liquidity Ratio inventivapharma.com
- financial results and valuation multiples details:
IVA - Net Profit|Company Profit Forecast Inventiva S.A.|IVA - Price to Earnings Ratio|Future Price to Earnings Inventiva Pharma|IVA - PEG Multiple|EV/EBITDA Multiple Inventiva|IVA - Operating profit before deduction of amortization|Earnings per share for the trailing year Inventiva|IVA - Earnings per share for the last twelve months|Year-over-year net earnings per share change for the last twelve months inventivapharma.com|IVA - Net earnings per share growth this year|Consensus forecast of earnings per share growth for next year Inventiva S.A.
- sales and revenue indicators:
IVA - Revenue and Sales Volume|Projected Sales Volume Inventiva Pharma|IVA - Market Cap to Revenue|Market Cap to Expected Sales Ratio Inventiva Pharma|IVA - Sales Growth YoY (TTM)
Fundamental company valuation:IVA, Inventiva SA
Finished products of Inventiva Corp

Professional managers utilize fundamental filters to distinguish speculative assets from sustainable businesses. This indicator measures the daily dynamics of earnings per share over the past year, allowing for an assessment of the revenue growth rates of Inventiva S.A. (IVA) prior to the commercialization of drugs for the treatment of metabolic disorders, which makes the annual percentage increase in EPS TTM a key marker of the company's financial viability during the clinical trial period.

Competitor analysis

Net earnings per share for the last four quarters Arrowhead Pharmaceuticals Inc ARWR|MIRM (Mirum Pharma) - Net earnings per share for the last 12 months|DVAX (Dynavax Technologies) - Earnings per share for the last twelve months|ABUS (Arbutus Biopharma Corp) - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months gyretx.com GYRE|Earnings per share for the last twelve months Assembly Biosciences, Inc. (ASMB)|GALT (Galectin Therapeutics Inc.) - Earnings per share for the trailing year|Net earnings per share (EPS TTM) GNFT (Genfit Corp)|DRRX: Earnings per share for the last 12 months|ALGS - Earnings per share for the last twelve months|Net earnings per share for the last four quarters BioVie BIVI|Galmed Pharmaceuticals Ltd (GLMD) - Earnings per share for the last twelve months|Earnings per share for the last 12 months NDRA|HEPA (Hepion Pharmaceuticals, Inc.) - Net earnings per share (EPS TTM)